Tag Archive for: SAB

Rewind Therapeutics Strengthens Scientific Advisory Board with Leading International Neurology Experts as it Advances First-in-Class Remyelination Therapy

/in

Professors Shiv Saidha, Cristina Granziera, David Leppert, and Roberto Furlan are world-renowned experts in neuroimaging, multiple sclerosis (MS) biomarkers, neuroimmunology, and translational drug development Appointments strengthen Rewind’s clinical experience as its GPR17 remyelination therapy advances toward clinical trials Leuven, Belgium – 18 June 2025 – Rewind Therapeutics, which is developing first-in-class treatments for demyelination-associated diseases, […]

Read more

Commit Biologics appoints leading industry experts to newly formed Scientific Advisory Board

/in

Industry and scientific experts in molecular biology, immunology and antibody research appointed to help develop Commit’s BiCE™ technology platform to treat autoimmune disease and cancer Leading antibody expert Janine Schuurman to co-chair Commit’s Scientific Advisory Board alongside Commit’s CEO Mikkel Wandahl Pedersen Joined by Paul Parren, Gavin Thurston, Susan Kalled, and Esper Boel on the […]

Read more

Ona Therapeutics Strengthens Leadership Team to Accelerate First-in-Class ADCs into Clinical Development Across Cancer Types

/in

Dr. Aleix Prat, an internationally recognized leader in drug and biomarker development appointed Chair of the Advisory Board Dr. Jutta Amersdorffer appointed as Chief Medical Officer and Stéphane Durant des Aulnois appointed as Chief Financial Officer Accelerating development of first-in-class ADCs in multiple large solid tumor types designed against novel targets with a focus on […]

Read more

Asceneuron Expands Scientific Advisory Board with World Leading Experts in Neurodegenerative Diseases

/in

Significant appointments of industry and academic experts to support Phase II development of ASN51 in Alzheimer’s disease Lausanne, SWITZERLAND and San Francisco, CA, USA, 6 March 2024 – Asceneuron SA, a clinical stage biotech company dedicated to targeting the root causes of neurodegenerative diseases, today announces the appointments of neurodegenerative disease experts to its Scientific Advisory Board […]

Read more

Destiny Pharma plc – Positive findings from recent SAB meeting

/in

Confirms proposed Phase 3 development pathway and identifies new life cycle management targets for XF-73 Nasal Brighton, United Kingdom – 6 July 2023 – Destiny Pharma (AIM: DEST), a clinical stage biotechnology company focused on the development and commercialisation of novel medicines to prevent life threatening infections, recently held a meeting with its Scientific Advisory Board […]

Read more